Holland Hospital Installs Masimo Noninvasive rainbow® Technology to Help Improve Patient Assessments and Speed Clinical Decisions

HOLLAND, Mich. and IRVINE, Calif., March 27, 2013 /PRNewswire/ -- Masimo (NASDAQ: MASI) announces that Holland Hospital, ranked as one of America's 100 Best Hospitals in 2013 by Healthgrades, is adding new clinical capabilities that allow clinicians to noninvasively and continuously monitor hemoglobin blood levels using Masimo SpHb^®.

Holland Hospital is now leveraging Masimo technology with noninvasive hemoglobin (SpHb) – clinically shown to reduce risky and unnecessary blood transfusions, and speed up necessary blood transfusions, while dramatically reducing costs – in its operating rooms.

"Our anesthesiologists started using Masimo Pulse CO-Oximetry technology for noninvasive hemoglobin monitoring during surgeries that took a long time and had the potential for a lot of blood loss, such as spinal surgeries," said Jeffrey Hodges, manager of the Cardiopulmonary Department at Holland Hospital. "Based on those results, the anesthesiologists then requested that the use of Masimo pulse oximeters be expanded to other floors."

Hemoglobin levels are used as a primary indicator for red blood cell (RBC) transfusion, but conventional laboratory measurements are only available intermittently and results can be delayed in the period between blood draw and laboratory analysis. This time gap of information can lead to sub-optimal transfusion decisions.¹ RBC transfusion overuse as well as delayed RBC transfusions can increase patient risk and cost of care. Multiple observational studies have shown that patients receiving RBC transfusions have an 88% higher mortality, 69% higher infection rate, and 250% higher rate of acute respiratory distress syndrome.²

SpHb monitoring provides real-time directional trends in hemoglobin, such as indicating stable hemoglobin when it may be perceived to be dropping, and rising hemoglobin when it may be perceived to not be rising fast enough. A recent award-winning studay from Cairo University in Egypt also showed that once clinicians determined a transfusion was needed, they were able to initiate transfusions 82% faster – in about 9 minutes, compared to about 50 minutes for patients not being monitored by SpHb.³ That same study also showed SpHb can help clinicians reduce unnecessary and risky RBC transfusions, which can improve patient outcomes while dramatically lowering the cost of care.

The use of SpHb is part of Holland Hospital's standardization to Masimo SET^® Measure-Through Motion and Low Perfusion™ pulse oximetry, shown to virtually eliminate false alarms⁴ and help clinicians better detect life-threatening events.⁵

"Like many health organizations, we're concerned about the safety of post-op patients on opioids, who are prone to respiratory depression," Hodges added. "With that in mind, we're making Masimo pulse oximetry a part of our standard of care."

Joe Kiani, founder and CEO of Masimo, stated: "We are honored that Holland Hospital, one of the top-performing hospitals in the nation with an inspiring reputation for excellence, has selected Masimo for its patient monitoring needs. As a forward-thinking healthcare organization that embraces best-in-class medical technologies, we are eager to help Holland Hospital improve its already superb patient safety and outcomes."

1 Friedman MT et al. Arch Pathol Lab Med. 2006 Apr;130(4):474-9.
2 Marik PE.et.al. Crit Care Med. 2008;36(9):2667-74
3 Wael NA, Maher F. Reduction in Red Blood Cell Transfusions during Neurosurgery with Noninvasive and Continuous Hemoglobin Monitoring. Proceedings of the Society for Technology in Anesthesia Annual Meeting ; 2013 Jan 9-12; Phoenix AZ. Available here.
4 Shah N, Ragaswamy H, Govindugari K, Estanol L. "Performance of three new-generation pulse oximeters during motion and low perfusion in volunteers." Journal of Clinical Anesthesia. 2012 (10.1016/j.jclinane.2011.10.012) Available online here
5 Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike, George T. "Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-and-After Concurrence Study." Anesthesiology, February 2010, Vol. 112, Issue 2. Available online here

About Holland Hospital
Holland Hospital serves the health care needs of the greater Holland area and surrounding communities in Ottawa and Allegan counties with a 189-bed main campus and numerous off-site locations. The hospital medical staff includes more than 300 primary care and specialty physicians with support from 2,000 hospital employees. Holland Hospital is ranked among the nation's 100 Top Hospitals by Truven Health (Thomson Reuters) and Healthgrades, and has received ISO 9001:2008 certification by DNV Healthcare. More information about the Truven Health 100 Top Hospitals 2013 award can be found online to [email protected]. Learn more about Holland Hospital's services and programs at hollandhospital.org

About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET^®, which virtually eliminated false alarms and increased pulse oximetry's ability to help clinicians detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET^® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow ^® Pulse CO-Oximetry™ technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures; total hemoglobin (SpHb^®), oxygen content (SpOC^™), carboxyhemoglobin (SpCO^®), methemoglobin (SpMet^®), PVI^®, and perfusion index (PI), in addition to measure-through motion SpO₂, and pulse rate. In 2008, Masimo introduced Patient SafetyNet™, a remote monitoring and wireless clinician notification system designed to help hospitals avoid preventable deaths and injuries associated with failure to rescue events. In 2009, Masimo introduced rainbow^® Acoustic Monitoring^™, the first-ever commercially available noninvasive and continuous monitoring of acoustic respiration rate (RRa™). Masimo SET^® and Masimo rainbow^® technologies also can be found in over 100 multiparameter patient monitors from over 50 medical device manufacturers around the world. Founded in 1989, Masimo has the mission of "Improving Patient Outcome and Reducing Cost of Care … by Taking Noninvasive Monitoring to New Sites and Applications^®." Additional information about Masimo and its products may be found at www.masimo.com.

Forward-Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including total hemoglobin (SpHb^®), contribute to positive clinical outcomes and patient safety in all patients and in every clinical situation; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including immediate and continuous results that enable earlier treatment without causing invasive trauma; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI, rainbow Acoustic Monitoring, RRa, Radical-7, Rad-87, Rad-57,Rad-8, Rad-5,Pulse CO-Oximetry, Pulse CO-Oximeter, Adaptive Threshold Alarm, and SEDLine are trademarks or registered trademarks of Masimo Corporation. The use of the trademarks Patient SafetyNet and PSN is under license from University HealthSystem Consortium.

SOURCE Masimo